Antares Pharma, Inc. (ATRS)

[jab91252]

Fyi: Teva presented today. At the very end of the Q&A, an analyst from Morgan Stanley asked about the epi-pen status. Elizabeth with TEVA answered, 'we plan to launch a generic epi-pen in 2015 and then we are looking into further improvements and innovation of the epi-pen but I will not comment further on that." hmmm.

Also, take a look at the "Supporting Materials" Teva R&D in Focus - New Therapeutic Entities pdf that comes with the presentation. Take a look at page 21, "Class of 2013" emerged following evaluation of >150 ideas slide. Does this remind anyone of someones else's slide??

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-EventDetails&EventId=5036013